However, seasoned pharmaceutical investors recognize the industry's cyclical nature. The industry's rhythm of drug development, regulatory hurdles, marketing pushes, and patent expirations means that ...

As we move further into October, many investors may be looking to identify certain stocks with the potential to provide ...

Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...

Two supercharged income stocks -- sporting yields of 5.6% and 5.8% -- have the tools and intangibles needed to catapult ...

In a previous interview, Lee hinted that a period of market volatility is expected, as 2024 heads for a soft landing.

Goldman Sachs senior biotechnology analyst in global investment research Chris Shibutani joins Market Domination Hosts Julie ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

Here are some of the major companies whose stocks moved on the week’s news.

ETFs such as The Schwab US Dividend ETF can be useful, but a 'DIY' approach can help you outperform. Here are 3 of the best ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer (PFE – Research Report), with a price ...

There was some intriguing news from a Pfizer (NYSE: PFE) shareholder on Thursday that was not taken well by the market.

US stocks declined on Thursday, with the S&P 500 and Dow Jones Industrial Average retreating from record highs amid signs of ...